English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 2 June 2025, 17:46 JST
Share:
    

Source: Eisai
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
- Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product -

TOKYO, June 2, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of “Pariet®S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1)

"Pariet S" is the first proton pump inhibitor (PPI(2)) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product(3), works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessiveacid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief.

Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical underthe brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders.

In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life.

For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets

(1) "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale
(2) Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process.
(3) Contains rabeprazole10mg per tablet

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
2025年6月2日 9時50分 JST
エーザイ、国内 OTC 医薬品初となるプロトンポンプ阻害薬「パリエット(R) S」新発売
2025年5月29日 11時30分 JST
エーザイ、米国におけるレンバチニブに関する特許侵害訴訟の勝訴について
Wednesday, 28 May 2025, 17:45 JST
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
Wednesday, 21 May 2025, 15:00 JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
2025年5月21日 9時00分 JST
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575